We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to ...

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read why PFE stock is a hold.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, ...

In the latest trading session, Pfizer (PFE) closed at $22.15, marking a +0.48% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the other ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...